Showing 1 - 10 of 43,451
costly orphan drugs because access depends primarily on co-payments, reimbursement policies and prices. The objective of this …
Persistent link: https://www.econbiz.de/10010614375
principles for reimbursement and pricing, and the use of generic drugs to lower prices. As a result of these changes …
Persistent link: https://www.econbiz.de/10004990333
Background:Background: The Common Drug Review (CDR) was created to provide a single process to review the comparative clinical efficacy and cost effectiveness of new drugs, and then to make formulary listing recommendations to Canadian publicly funded drug benefit plans. Abstract:...
Persistent link: https://www.econbiz.de/10009493382
Reimbursement Committee (DRC) evaluates reimbursement requests for orphan drugs based on multiple criteria: the therapeutic value …, price and proposed reimbursement tariff; the importance of the drug in clinical practice; and the budget impact of the drug …. Objectives: This study aimed to assess reimbursement dossiers of orphan drugs in Belgium and to compare them with the clinical …
Persistent link: https://www.econbiz.de/10010614358
Background: Attempts to improve the acceptability of resource allocation decisions around new health technologies have spanned many years, fields and disciplines. Various theories of decision making have been tested and methods piloted, but, despite their availability, evidence of sustained...
Persistent link: https://www.econbiz.de/10010614366
Asian healthcare systems are very diverse, representing cultures, political systems and economies from more than 30 countries with varying histories. Despite the diversity in the region, there has been enormous growth in health economics and outcomes research since the beginning of the 21st...
Persistent link: https://www.econbiz.de/10008519880
particular focus on the processes of HTA for listing medications on public formularies. Four of the committees evaluating … managed separately in other HTA organizations; (iii) because of the link between HTA and reimbursement decisions, completion … reimbursement in the jurisdictions explored - without this link the role of CER in the US will remain advisory; (v) each …
Persistent link: https://www.econbiz.de/10008519883
Persistent link: https://www.econbiz.de/10008519897
The National Institute for Health and Clinical Excellence (NICE) is required to consider cost effectiveness when issuing guidance about the use of health technologies within the UK NHS. Cost effectiveness is a means of supporting a system objective of maximizing population health gain from the...
Persistent link: https://www.econbiz.de/10005449021
licensing bodies and public reimbursement agencies. The present study compares access to licensed and subsidized medicines under …
Persistent link: https://www.econbiz.de/10010579442